(Bloomberg) -- Private equity firms Advent International and PAI Partners are among suitors that submitted first-round offers for French drugmaker Sanofi SA’s consumer health division, according to people familiar with the matter. Most Read from Bloomberg US Floats Tougher Trade Rules to Rein In China Chip Industry High-Flying Chip Stocks Hit by Risk of US Curbs: Markets Wrap BlackRock Says Gunman From Trump Rally Appeared in Firm’s Ad Trump Security Tightened on Iran Plot Intel; No Link to Shooting Amazon Sold a Used Diaper. It Tanked a Mom-and-Pop Business Buyout firm Clayton Dubilier & Rice has also put in an initial bid for the Sanofi business, which sells over-the-counter products including Phytoxil cough syrups and Icy Hot pain relief gels, the people said. Some of the proposals valued the unit at as much as €15 billion ($16 billion), the people said. CVC Capital Partners Plc and a separate consortium of Bain Capital and Cinven didn’t submit bids by the deadline, according to the people, who asked not to be identified as the information is private. Deliberations are ongoing, and some suitors could opt to team up later in the process, the people said. More bidders could still emerge, they added. Spokespeople for Advent, Bain, CD&R, Cinven, CVC and PAI declined to comment. Sanofi is reviewing potential separation scenarios for the consumer health business with a transaction in the fourth quarter of 2024 at the earliest, a representative for the firm said, adding that the preparation is on track. “We are keeping all options open, including a listing, and a sale, to maximize value creation for all our stakeholders,” the representative said. Sanofi announced its plans to review all options to split the consumer health unit last October, as it looks to generate better long-term value from cutting-edge therapies, particularly in immunology or in vaccines. The drugmaker is likely to retain a significant minority stake in the business after any sale, which would reduce the amount of capital that bidders need to commit, people familiar with the matter have said. It’s also simultaneously moving forward with preparations for a possible listing of the business. Sanofi Chief Executive Officer Paul Hudson said in a Bloomberg Television interview earlier this month that the company is talking to all interested parties, including private equity, with a capital markets option available to the company too. “There’s a huge amount of interest,” he said. PAI has been hoping its status as the only French bidder should place it in a pole position to buy the business, Bloomberg News has reported. French state-own investment firm Bpifrance SACA is also looking at a potential investment the Sanofi arm and may team up with the winning bidder, its executive director Jose Gonzalo told reporters on July 4. A potential sale of the OTC business could rank among the largest deals in Europe this year. It’s also progressing after the left-wing group surprisingly won a snap parliamentary election in France earlier this month, denying Marine Le Pen’s far-right coalition from getting a majority. President Emmanuel Macron on Tuesday appointed a caretaker government as negotiations to find a new prime minister continue. Most Read from Bloomberg Businessweek Top Takeaways From Businessweek’s Donald Trump Interview Why the Nobel-Laureate Pioneer of Microfinance Risks Life in Jail Interviewing Trump on His Plans for the US Economy How Trader Joe’s Mini Cooler Bags Became a Viral Hit What Americans Invest In Now ©2024 Bloomberg L.P.
Sanofi’s Consumer Arm Said to Draw Bids From Advent, PAI, CD&R
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...